A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers
Latest Information Update: 07 Aug 2023
At a glance
- Drugs HSK 31858 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
- 12 Jul 2022 Status changed from recruiting to completed.
- 27 Oct 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2021 to 28 Oct 2021.
- 27 Oct 2021 Status changed from not yet recruiting to recruiting.